| Market Cap | 7.45M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | 763.08k | Forward P/E | - | EPS next Y | - | 50D Avg Chg | -15.00% |
| Sales | 353.74k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 12.00% |
| Dividend | N/A | Price/Book | N/A | EPS next 5Y | - | 52W High Chg | -38.00% |
| Recommedations | - | Quick Ratio | 0.09 | Shares Outstanding | 65M | 52W Low Chg | 125.00% |
| Insider Own | 59.39% | ROA | -153.34% | Shares Float | 23.06M | Beta | 0.83 |
| Inst Own | - | ROE | - | Shares Shorted/Prior | -/- | Price | 0.11 |
| Gross Margin | 100.00% | Profit Margin | 215.72% | Avg. Volume | 5,564 | Target Price | - |
| Oper. Margin | -74.14% | Earnings Date | Nov 26 | Volume | 50 | Change | 0.00% |
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy to treat tendon injuries, androgenetic alopecia, and skin aging by restoring cellular function to rejuvenate aging or sun damaged skin, regrow hair, and repair tendons. The company's product candidates include RCH-01, a cell therapy for pattern baldness; RCS-01, a cell therapy foraging or sun damaged skin; and RCT-01, a cell therapy for tendon degeneration. It is also developing DermaPrecise, a dermal injection device. The company has a licensing and collaborative agreement with YOFOTO (China) Health Industry Co. Ltd. to develop and commercialize RCS-01, RCT-01, and DermaPrecise. RepliCel Life Sciences Inc. is based in Vancouver, Canada.